SWISS MEDICAL NETWORK



Dr méd. Michael Montemurro

Spécialiste FMH en Hématologie
Spécialiste FMH en Médecine Interne
Spécialiste en Médecine interne, Hématologie et Oncologie médicale

Langues

EN,DE,FR,IT

Expérience professionnelle

Depuis 2021	Consultant, Oncologie médicale, University College London Hospitals, UK
2020	Médecin Chef, Oncologie médicale, EHC Morges Hospital, CH
2016–2020	Médecin Adjoint, Oncologie médicale, CHUV Lausanne, CH
2014–2015	Médecin Associé, Oncologie médicale, IOSI-EOC, Ospedale Bellinzona, CH
2013–2014	Sarcoma Unit, The Royal Marsden Hospital London, UK
2012	Oncologie médicale, CHU Zürich, CH
2005–2012	Centre Pluridisciplinaire d'Oncologie (CePO), CHUV Lausanne, CH

Formation

2019	ESMO Examination Oncologie médicale
2003	Hématologie et Oncologie interne
2002	Médecine interne
1999	Thèse de recherche, Faculté de médecine, Université Essen, Allemagne
1989–1995	Médecine, Johann Wolfgang Goethe Universität, Frankfurt, Allemagne

Compétences

- Tumeurs digestives : colon, rectum, foie, pancréas, estomac, oesophage, neruo-endocrine)
- GIST (tumeur gastrointestinale stromale)
- Sarcomes des tissus mous et osseux

Affiliations

- 2009 – 2020 : ESMO Faculty Member GIST / Sarcoma (ESMO Guidelines Sarcoma, GIST)
- 2011 – 2016 : Président SAKK project group "Gastrointestinal Cancer"
- 14.01.2010 : Membre fondateur "Groupe GIST Suisse"

Publications

Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Montemurro, M. et al. 2021 Feb;27(2):289-300

Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma. Dunet V, Halkic N, Sempoux C, Demartines N, Montemurro M, Prior JO, Schmidt S.; Eur Radiol. 2021 Feb;31(2):992-1001

LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
Montemurro, M., et al. Cell Rep. 2020 Mar 31;30(13):4567-4583

Oncological outcome, functional results and costs after unplanned excision of musculoskeletal soft tissue sarcoma
Morattel , Mustaki, Montemurro, Letovanec, Durham, Becce, Omoumi, di Summa, Matter, Rüdiger , Cherix
Eur J Surg Oncol. 2020 May;46(5):898-904

Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis ....
Du Pasquier C, Roulin D, Bize P, Sempoux C, Rebecchini C, Montemurro M, Schäfer M, Halkic N, Demartines N.
BMC Surg. 2020 Apr 19;20(1):78

Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer.
De Bari B, Franzetti-Pellanda A, Saidi A, Biggiogero M, Hahnloser D, Montemurro M, Bourhis J, Zeverino M, Ozsahin M. J Cancer Res Clin Oncol. 2019 Apr;145(4):1075-1084

Long-term outcome of dasatinib first-line treatment in GIST: A multicenter, 2-stage phase 2 trial (SAKK 56/07).
Montemurro M et al.; Cancer. 2018 Apr 1;124(7):1449-1454

Sarcoma of the heart: survival after surgery.
Niclauss L, Montemurro M, Kirsch M, Prêtre R.; Interact Cardiovasc Thorac Surg. 2018 Aug; 27(2):198-201

Radiation Therapy for GIST Progressing During Or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study
Joensuu H, Eriksson M, Collan J, Balk M, Leyvraz S, Montemurro M; Radiother Oncol. 2015 Aug; 116(2):233-8

Survival after surgical drainage of malignant pericardial effusion
Niclauss L, Montemurro M, Prêtre R; World J Surg 2015 Jul;39(7):1767

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour .....
M. Montemurro et al.; European Journal of Cancer 2013 Mar;49(5):1027-31

Continuous Sunitinib treatment in patients with advanced HCC: a SAKK and SASL multicenter phase II trial (SAKK 77/06). Koeberle D, Montemurro M et al.; Oncologist. 2010;15(3):285-92.

Early prediction of response to sunitinib after imatinib failure by 18F-FDG-PET in patients with GIST
Prior JO, Montemurro M et al. ; J Clin Oncol. 2009 Jan 20;27(3):439-45. Epub 2008 Dec 8.
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Montemurro M et al.; Eur J Cancer. 2009 Sep;45(13):2293-7

PCNSL treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell
transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OSHO-53 phase II study. Montemurro M et al.; Ann Oncol. 2007 Apr;18(4):665-71.

Chapitre de Livre

Principles of Tumor Therapy
In: “HEROLD – INNERE MEDIZIN”, Gerd Herold (editeur), Germany; since 2010, mis à jour annuelle

Prix

- 2018 : Prix annuel du Groupe GIST Group Suisse

- 2012 : Prix annuel du Groupe GIST Group Suisse
- 2011 : Prix d'honneur du Groupe GIST Group Suisse pour "Living with GIST"
- 2011 : Edi 2011 (argent): Film documentaire "Living with GIST"
- 2011 : Membre d'honneur du groupe GIST Suisse (www.gist.ch)
- 2010 : Prix annuel du Groupe GIST Group Suisse

Accréditation

Clinique de Genolier

Clinique de Montchoisi

Spécialités

Hématologie

Médecine interne générale

Oncologie

Onco-hématologie

Contactez-nous

Clinique de Genolier
Route du Muids 3
1272 Genolier

T T +41 22 366 90 72
fmansouri@genolier.net

Téléchargez la vCard